Clinical and Experimental Medicine · 2023 · 42 citations · 29 references
MedicineOncologyPharmacologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationImmune Checkpoint Blockade CombinationsImmune Checkpoint Inhibitor TherapyImmunomodulatory EffectsPi3k InhibitorsResistance To Checkpoint InhibitorsResistance To Immune Checkpoint InhibitionSyngeneic Tumor ModelsTumor Immune Cell Infiltration
Abstract The PI3K pathway is one of the most frequently altered signaling pathways in human cancer. In addition to its function in cancer cells, PI3K plays a complex role in modulating anti-tumor immune responses upon immune checkpoint inhibition (ICI). Here, we evaluated the effects of the pan-Class I PI3K inhibitor copanlisib on different immune cell types in vitro and on tumor growth and immune cell infiltration in syngeneic murine cancer models. Intermittent treatment with copanlisib resulted in a strong in vivo anti-tumor efficacy, increased tumor infiltration of activated T cells and macrophages, and increased CD8 + T cell/regulatory T cell and M 1/ M 2 macrophage ratios. The strong in vivo efficacy was at least partially due to immunomodulatory activity of copanlisib, as in vitro these murine cancer cells were resistant to PI3K inhibition. Furthermore, the combination of copanlisib with the ICI antibody anti-PD-1 demonstrated enhanced anti-tumor efficacy in both ICI-sensitive and insensitive syngeneic mouse tumor models. Importantly, in an ICI-sensitive model, combination therapy resulted in complete remission and prevention of tumor recurrence. Thus, the combination of ICIs with PI3K inhibition by intermittently dosed copanlisib represents a promising new strategy to increase sensitivity to ICI therapies and to treat human solid cancers.
29
QuPath: Open source software for digital pathology image analysis
Peter Bankhead, Maurice B. Loughrey, José A. Fernández et al. · Scientific Reports · 2017 · 8.7K citations · Full text
Medicine, Cancer Biology, Pathology +17
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text
Life Sciences, Immunology, Pathology +14
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger, Riyue Bao, Thomas F. Gajewski · Nature · 2015 · 2.8K citations
Medicine, Cancer Biology, Oncology +10
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng, Jie Qing Chen, Chengwen Liu et al. · Cancer Discovery · 2015 · 1.5K citations · Full text
Medicine, Immunology, Oncology +17
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau, Matthew Rausch, David A. Winkler et al. · Nature · 2016 · 865 citations
Medicine, Cancer Biology, Oncology +14